Related Experiment Video
Updated: May 14, 2026
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Lipid Nanoparticle-Based αHTRA1 mRNA Improves Pancreatic Ductal Adenocarcinoma Redox Microenvironment by Suppressing
Xinya Zhao1,2, Xufeng Tao1, Hong Xiang3
1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian116011, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with an inferior prognosis, and currently, there is a lack of effective treatment options. In immunotherapy, messenger RNA (mRNA)-based drugs, especially mRNA vaccines, have shown great potential in recent years. Previous research has found that high-temperature requirement protein A1 (HTRA1) is upregulated in PDAC and is a key factor in disease progression. Based on this key discovery, we have developed an mRNA drug based on lipid nanoparticles (LNP), which utilizes the efficient delivery capability of LNP to achieve precise delivery of antibodies targeting HTRA1 in vivo, thereby directly inhibiting the expression of HTRA1 in tumor cells. As a delivery carrier, LNP not only improves the stability and bioavailability of mRNA but also enhances its enrichment and release efficiency in tumor tissues. This study confirms that anti-HTRA1 (αHTRA1) mRNA can effectively inhibit the malignant phenotype of PDAC cells. Furthermore, we have established C57BL/6 wild-type (WT) and LSL-KrasG12D/+; Pdx1-Cre (KC) mouse pancreatic organoid models, and the results indicate that the drug, by inhibiting the hypoxia-inducible factor-1 (HIF-1) signaling pathway, improves the tumor microenvironment and can effectively suppress the progression of PDAC. The mRNA drugs based on LNP designed and synthesized in this study have good therapeutic potential for PDAC, providing new potential drugs for targeted therapy of PDAC.
Insights
This study introduces a novel messenger RNA (mRNA) drug using lipid nanoparticles (LNP) to target high-temperature requirement protein A1 (HTRA1) in pancreatic cancer. This LNP-mRNA therapy effectively inhibits PDAC progression by improving the tumor microenvironment.
Area of Science:
- Oncology
- Immunotherapy
- Drug Delivery Systems
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options.
- High-temperature requirement protein A1 (HTRA1) is overexpressed in PDAC and drives disease progression.
- Messenger RNA (mRNA) therapeutics, particularly mRNA vaccines delivered via lipid nanoparticles (LNP), show promise in cancer treatment.
Purpose of the Study:
- To develop and evaluate an LNP-based mRNA drug targeting HTRA1 for PDAC therapy.
- To assess the efficacy of anti-HTRA1 (αHTRA1) mRNA in inhibiting PDAC cell malignancy.
- To investigate the drug's impact on the tumor microenvironment and PDAC progression in preclinical models.
Main Methods:
- Development of an LNP-encapsulated mRNA drug designed to deliver antibodies targeting HTRA1.
- In vitro assessment of αHTRA1 mRNA's effect on PDAC cell phenotype.
- Establishment of C57BL/6 wild-type and LSL-KrasG12D/+; Pdx1-Cre (KC) mouse pancreatic organoid models for in vivo evaluation.
Main Results:
- The LNP-based αHTRA1 mRNA drug effectively inhibited the malignant phenotype of PDAC cells.
- Treatment suppressed PDAC progression in preclinical mouse models.
- The therapy was found to improve the tumor microenvironment by inhibiting the hypoxia-inducible factor-1 (HIF-1) signaling pathway.
Conclusions:
- LNP-delivered αHTRA1 mRNA demonstrates significant therapeutic potential for pancreatic ductal adenocarcinoma.
- This novel mRNA drug offers a promising new avenue for targeted PDAC therapy.
- The study highlights the effectiveness of LNP-mRNA technology in modulating the tumor microenvironment and suppressing cancer progression.
